Astellas Pharma withdraws lawsuit challenging USA's IRA

Japanese pharma major Astellas Pharma (TYO: 4503) revealed that it has requested that the Court dismiss the company’s lawsuit challenging the constitutionality of certain provisions of the US government’s Inflation Reduction Act (IRA).

However, the company points out that its decision to withdraw the case does not change its fundamental belief that in its current form, the Medicare Drug Price Negotiation Program (Program) created by the IRA is bad policy and unconstitutional.

The move comes after Astellas’ flagship cancer drug Xtandi (enzalutamide) was spared from the list of 10 drugs up for the first-ever price negotiations under the IRA.